Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus TRYMEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus TRYMEX.
CORTENEMA vs TRYMEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
TRYMEX is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, enhancing neurotransmission in the central nervous system.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Adults: 500 mg orally twice daily or 1 g intravenously once daily.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 30-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal excretion of unchanged drug accounts for 60-70% of dose; biliary/fecal elimination contributes 20-30%, with <5% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid